Xu Yingying, Zhao Huanyu, Tong Yusuo, Wang Wanwei, Huang Jing, Zhu Weiguo
Department of Radiation Oncology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, 223300, People's Republic of China.
Department of Pathology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, 223300, People's Republic of China.
Int J Gen Med. 2021 Jul 26;14:3929-3939. doi: 10.2147/IJGM.S314054. eCollection 2021.
Basaloid squamous cell carcinoma (BSCC) is a rare variant of squamous cell carcinoma (SCC) of the esophagus. This study aimed to assess the discrepancy in clinicopathological characteristics and protein expression between esophageal BSCC and typical esophageal SCC.
We reviewed 40 cases of esophageal BSCC. As controls, 63 well-differentiated SCC (WSCC) patients, 70 moderately differentiated SCC (MSCC) patients, and 51 poorly differentiated SCC (PSCC) patients were selected. The clinicopathologic characteristics and immunoreactivity of Ki-67, p53, p63, and epidermal growth factor receptor (EGFR) were then evaluated in the BSCC and typical SCC patients.
The 5-year survival rates for the BSCC patients were 27.5%. The prognostic outcomes of the BSCC group were similar to those of the PSCC and MSCC groups but worse than that of the WSCC group, with a significant difference (P=0.045). Ki-67 expression was significantly higher in the BSCC group than that in the WSCC group (P < 0.05). Meanwhile, there were no significant differences in the expression of the other molecular markers (p53, p63, and EGFR) between the typical SCC and BSCC groups (P > 0.05). The median survival time of esophageal the BSCC patients with low p53 expression was significantly longer than that of the patients with high p53 expression (P=0.026). Further, the median survival time of the esophageal BSCC patients with high p63 expression was significantly longer than that of the patients with low p63 expression (P=0.041). Meanwhile, Ki-67 and EGFR expressions were not correlated with OS in the BSCC group.
Esophageal BSCC has a more clinically virulent course. Notably, p53 and p63 expression are associated with prognosis in BSCC. These findings conject that evaluation of multiple cancer biomarkers might be a promising auxiliary diagnostic indicator in BSCC.
基底样鳞状细胞癌（BSCC）是食管鳞状细胞癌（SCC）的一种罕见变体。本研究旨在评估食管BSCC与典型食管SCC在临床病理特征和蛋白表达方面的差异。
我们回顾了40例食管BSCC病例。作为对照，选取了63例高分化SCC（WSCC）患者、70例中分化SCC（MSCC）患者和51例低分化SCC（PSCC）患者。然后评估了BSCC和典型SCC患者的临床病理特征以及Ki-67、p53、p63和表皮生长因子受体（EGFR）的免疫反应性。
BSCC患者的5年生存率为27.5%。BSCC组的预后结果与PSCC组和MSCC组相似，但比WSCC组差，差异有统计学意义（P = 0.045）。BSCC组中Ki-67的表达明显高于WSCC组（P < 0.05）。同时，典型SCC组和BSCC组之间其他分子标志物（p53、p63和EGFR）的表达没有显著差异（P > 0.05）。p53低表达的食管BSCC患者的中位生存时间明显长于p53高表达的患者（P = 0.026）。此外，p63高表达的食管BSCC患者的中位生存时间明显长于p63低表达的患者（P = 0.041）。同时，BSCC组中Ki-67和EGFR的表达与总生存期无关。
食管BSCC的临床病程更具侵袭性。值得注意的是，p53和p63的表达与BSCC的预后相关。这些发现推测，评估多种癌症生物标志物可能是BSCC中有前景的辅助诊断指标。
